Get the Stockscreener App
0.89
6.41%
-0.061
After Hours:
.91
0.02
+2.25%
Moleculin Biotech Inc stock is traded at $0.89, with a volume of 354.89K.
It is down -6.41% in the last 24 hours and down -16.04% over the past month.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
See More
Previous Close:
$0.951
Open:
$0.93
24h Volume:
354.89K
Relative Volume:
0.28
Market Cap:
$12.58M
Revenue:
-
Net Income/Loss:
$-29.77M
P/E Ratio:
-0.0582
EPS:
-15.2954
Net Cash Flow:
$-24.23M
1W Performance:
-9.17%
1M Performance:
-16.04%
6M Performance:
-66.91%
1Y Performance:
-81.95%
1-Day Range:
$0.86
$0.935
1-Week Range:
$0.86
$0.9835
52-Week Range:
$0.3975
$5.115
Moleculin Biotech Inc Stock (MBRX) Company Profile
Name
Moleculin Biotech Inc
Sector
Industry
Phone
713-300-5160
Address
5300 MEMORIAL DRIVE, HOUSTON, TX
Compare MBRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
0.89 | 14.04M | 0 | -29.77M | -24.23M | -15.30 |
|
ONC
Beigene Ltd Adr
|
238.31 | 25.23B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
446.00 | 113.16B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.26 | 40.65M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.26 | 64.41B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
75.61 | 6.18B | 0 | -153.72M | -103.81M | -2.00 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-25 | Downgrade | Maxim Group | Buy → Hold |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
Moleculin Biotech Inc Stock (MBRX) Latest News
Moleculin receives Nasdaq non-compliance notice By Investing.com - Investing.com South Africa
Moleculin Biotech Faces Nasdaq Non-Compliance Notice - TipRanks
Moleculin receives Nasdaq non-compliance notice - Investing.com
Moleculin signals first 45-patient unblinding for Phase 3 AML trial by end of 2025 as key regulatory milestones achieved - MSN
Q2 EPS Forecast for Moleculin Biotech Increased by Analyst - Defense World
Moleculin Biotech reaches agreement to amend investor warrants - MSN
MBRX stock touches 52-week low at $1.46 amid sharp yearly decline - MSN
Moleculin Announces First European Approval for Phase 3 AML Trial - MSN
Moleculin Biotech’s Earnings Call: Trials and Triumphs - TipRanks
Moleculin Biotech, Inc. (NASDAQ:MBRX) Q1 2025 Earnings Call Transcript - Insider Monkey
Moleculin Biotech Inc (MBRX) Q1 2025 Earnings Call Highlights: Strategic Advances and Financial ... - Yahoo Finance
Moleculin Biotech Inc (MBRX) Q1 2025 Earnings Call Highlights: S - GuruFocus
Moleculin Biotech Reports Q1 2025 Financial Results - TipRanks
Moleculin Biotech Gets EMA Nod For Leukemia Trial: Retail Feels Bullish On ‘Low And Slow’ Setup - MSN
Transcript : Moleculin Biotech, Inc., Q1 2025 Earnings Call, May 14, 2025 - marketscreener.com
Earnings call transcript: Moleculin Biotech reports Q1 2025 updates By Investing.com - Investing.com India
Earnings call transcript: Moleculin Biotech reports Q1 2025 updates - Investing.com
Moleculin Reports First Quarter 2025 Financial Results and Provi - GuruFocus
Moleculin (MBRX) Advances Phase 3 MIRACLE Trial with Global Prog - GuruFocus
Moleculin (MBRX) Advances Phase 3 MIRACLE Trial with Global Progress | MBRX Stock News - GuruFocus
Moleculin Biotech reports Q1 EPS (69c) vs ($2.02) last year - TipRanks
Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Moleculin's AML Treatment Trial Gets Major EU Expansion as Q1 Results Reveal Timeline for Critical Data - Stock Titan
MOLECULIN BIOTECH Earnings Results: $MBRX Reports Quarterly Earnings - Nasdaq
Moleculin Biotech, Inc. SEC 10-Q Report - TradingView
EMA approves Moleculin’s application for Phase IIb/III AML trial - Yahoo
Moleculin expands EU trial for leukemia treatment By Investing.com - Investing.com South Africa
Moleculin Biotech (MBRX) Gains EMA Approval for Pivotal Phase 2B/3 AML Trial | MBRX Stock News - GuruFocus
Moleculin Receives European Medicines Agency Approval to Expand - GuruFocus
Moleculin expands EU trial for leukemia treatment - Investing.com Australia
Moleculin Receives European Medicines Agency Approval To Expand Phase 3 Miracle Clinical Trial - marketscreener.com
Moleculin Biotech’s Annamycin Trial Approved by EMA - TipRanks
Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial - The Manila Times
Moleculin Biotech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow
Moleculin Biotech Cancels Special Meeting Due to Lack of Quorum By Investing.com - Investing.com India
Moleculin Biotech Cancels Special Meeting Due to Lack of Quorum - Investing.com Australia
Moleculin Biotech Cancels Special Stockholders Meeting - TipRanks
Moleculin Biotech Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders - Quantisnow
Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML) - Seeking Alpha
Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast - Seeking Alpha
Moleculin Biotech to Announce Q1 2025 Financial Results - TipRanks
Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast - The Manila Times
Moleculin Biotech Inc expected to post a loss of 56 cents a shareEarnings Preview - TradingView
Moleculin Biotech (MBRX) Gains WHO Approval for Annamycin's Non- - GuruFocus
Moleculin Biotech (MBRX) Gains WHO Approval for Annamycin's Non-proprietary Name | MBRX Stock News - GuruFocus
Moleculin Biotech’s Annamycin Receives WHO Name Approval - TipRanks
Moleculin Biotech Inc Stock (MBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.00%
0.96%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):